Voluntis Announces Issuance of European Patent for Drug Dosing Support With Its Theraxium Digital Therapeutic Platform
15 Fevereiro 2021 - 4:00AM
Business Wire
- Patented technology used to assist patients in optimizing
their drug dosage through intelligent and adaptive
algorithms
- Expansion of Voluntis' existing intellectual property
portfolio in the field of digital therapeutics
- Application in the field of diabetes for insulin titration
support
Regulatory News:
Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN:
FR0004183960), a leader in digital therapeutics, announced today
the issuance of a new patent by the European Patent Office (EPO)
for intelligent patient support in drug dosing applied in the field
of diabetes for insulin titration support.
Following the prescription of the drug and its companion digital
therapeutic, the intelligent and adaptive algorithms developed by
Voluntis will automatically recommend to a patient, day by day and
according to the evolution of their monitoring data, a progressive
increase of the dose to bring the patient into the target range as
specified by their physician. Safety mechanisms are also present to
decrease the dose if the situation requires it. Once the target
range is reached, the dose will then remain stable as long as the
patient's follow-up data stays within the target range.
In the field of diabetes, the patent obtained relates to the
optimization of insulin titration, based on the evolution of
fasting blood glucose levels over several days to recommend to the
patient an appropriate dose of basal insulin to be injected, in
accordance with their treatment plan. More specifically, this new
patent covers the management of the sensitivity of the titration
algorithms to changes in the patient's blood glucose levels to
optimize the achievement and maintenance of the dose enabling
glycemic control.
"Thanks to this patented technology, we are extending the scope
of cutting-edge solutions available to our clinical and industrial
partners wishing to offer unique treatment experiences to patients
worldwide" said Pierre Leurent, Chief Executive Officer.
"Successfully dosing drug treatments, particularly in the context
of complex therapies, is often a challenge for patients and their
healthcare teams, Digital therapeutics now provide innovative
solutions thanks to embedded algorithms that provide patients with
daily and personalized recommendations, in compliance with the
physician's prescription and with performance and safety standards.
".
"We are proud to obtain this new patent, which builds on
Voluntis' 15 years of experience in the field of dosage support
with digital therapeutics" added Etienne Vial, Chief Technology
Officer. "Our Theraxium platform is already being used for drug
dosing support in therapeutic areas other than diabetes,
particularly in oncology for the dosing of symptomatic treatments.
These developments in our platform offer promise to further extend
our approach to other therapeutic areas. »
About Voluntis
Voluntis creates digital therapeutics that empower people with
chronic conditions to self-manage their treatment every day, thus
improving real-world outcomes. Voluntis’ solutions, combining
mobile and web apps, use clinical algorithms to deliver
personalized recommendations to patients and their care teams. For
example, these recommendations are used to adjust treatment dosage,
manage side effects or monitor symptoms.
Leveraging its Theraxium technology platform, Voluntis has
designed and operates multiple digital therapeutics, especially in
oncology and diabetes. Voluntis has long-standing partnerships with
leading life science companies. Based in Cambridge, MA, and Paris,
France, Voluntis is a founding member of the Digital Therapeutics
Alliance.
For more information, please visit: www.voluntis.com
Mnemo : VTX - ISIN : FR0004183960
Disclaimer
This press release contains certain forward-looking statements
concerning Voluntis group and its business, including its prospects
and product candidate development. Such forward-looking statements
are based on assumptions that Voluntis considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
2019 annual financial report and the 2020 half-year financial
report published by Voluntis respectively on April 30, 2020 and
September 29, 2020 (a copy of which is available on
www.voluntis.com) and to the development of economic conditions,
financial markets and the markets in which Voluntis operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Voluntis or not currently
considered material by Voluntis. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Voluntis to be materially different
from such forward-looking statements. Voluntis expressly declines
any obligation to update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210214005034/en/
ACTUS Media relations Vivien Ferran vferran@actus.fr +33
(0)1 53 67 36 34
ACTUS Investor relations Jérôme Fabreguettes-Leib
voluntis@actus.fr +33 (0)1 53 67 36 78
Voluntis Chief Financial Officer Guillaume Floch
investisseurs@voluntis.com +33 (0)1 41 38 39 20